CD147 regulates antitumor CD8+ T-cell responses to facilitate tumor-immune escape
- 11 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cellular & Molecular Immunology
- Vol. 18 (8), 1995-2009
- https://doi.org/10.1038/s41423-020-00570-y
Abstract
Negative regulation of antitumor T-cell-immune responses facilitates tumor-immune escape. Here, we show that deletion of CD147, a type I transmembrane molecule, in T cells, strongly limits in vivo tumor growth of mouse melanoma and lung cancer in a CD8+ T-cell-dependent manner. In mouse tumor models, CD147 expression was upregulated on CD8+ tumor-infiltrating lymphocytes (TILs), and CD147 was coexpressed with two immune-checkpoint molecules, Tim-3 and PD-1. Mining publicly available gene-profiling data for CD8+ TILs in tumor biopsies from metastatic melanoma patients showed a higher level of CD147 expression in exhausted CD8+ TILs than in other subsets of CD8+ TILs, along with expression of PD-1 and TIM-3. Additionally, CD147 deletion increased the abundance of TILs, cytotoxic effector function of CD8+ T cells, and frequency of PD-1+ CD8+ TILs, and partly reversed the dysfunctional status of PD-1+Tim-3+CD8+ TILs. The cytotoxic transcription factors Runx3 and T-bet mediation enhanced antitumor responses by CD147–/– CD8+ T cells. Moreover, CD147 deletion in T cells increased the frequency of TRM-like cells and the expression of the T-cell chemokines CXCL9 and CXCL10 in the tumor microenvironment. Analysis of tumor tissue samples from patients with non-small-cell lung cancer showed negative correlations between CD147 expression on CD8+ TILs and the abundance of CD8+ TILs, histological grade of the tumor tissue samples, and survival of patients with advanced tumors. Altogether, we found a novel function of CD147 as a negative regulator of antitumor responses mediated by CD8+ TILs and identified CD147 as a potential target for cancer immunotherapy.Keywords
This publication has 53 references indexed in Scilit:
- CD147 in regulatory T cellsCellular Immunology, 2013
- A novel anti-EMMPRIN function-blocking antibody reduces T cell proliferation and neurotoxicity: relevance to multiple sclerosisJournal of Neuroinflammation, 2012
- CD147 (Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+-activated human regulatory T cellsBlood, 2011
- Involvement of HAb18G/CD147 in T cell activation and immunological synapse formationJournal of Cellular and Molecular Medicine, 2010
- Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLsThe Journal of Experimental Medicine, 2009
- Targeting the chemotactic function of CD147 reduces collagen‐induced arthritisImmunology, 2008
- CD147 Inhibits the Nuclear Factor of Activated T-cells by Impairing Vav1 and Rac1 Downstream SignalingOnline Journal of Public Health Informatics, 2008
- Inhibition of CD147 Gene Expression via RNA Interference Reduces Tumor Cell Proliferation, Activation, Adhesion, and Migration Activity in the Human Jurkat T-Lymphoma Cell LineCancer Investigation, 2008
- Emmprin, a cell surface inducer of matrix metalloproteinases (MMPs), is expressed in T‐cell lymphomasThe Journal of Pathology, 2004
- T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen densityInternational Immunology, 1999